Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 5/20 | 1.00 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | CRHBP | P24387 | 1/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | JUN | P05412 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30830946 | 1.00 | CYP2A6 (1.00) | CYP2A6CA1CA2CHRNA7SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1237491 | 0.98 | CYP2A6 (0.96) | CYP2A6CA1CA2CHRNA7SMN1; SMN2 | |
| SCHEMBL277679 | 0.83 | CYP2A6 (0.71) | CYP2A6CA1CA2CHRNA7SMN1; SMN2 | |
| SCHEMBL31547776 | 0.83 | CYP2A6 (0.71) | CYP2A6CA1CA2CHRNA7SMN1; SMN2 | |
| SCHEMBL3106949 | 0.83 | CYP2A6 (0.70) | CYP2A6CA1CA2CHRNA7SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2967756 | 0.82 | CYP2A6 (0.69) | CYP2A6CA1CA2CHRNA7SMN1; SMN2 | |
| SCHEMBL5235492 | 0.80 | CYP2A6 (0.67) | CYP2A6CA1CA2CHRNA7SMN1; SMN2 | |
| SCHEMBL2248829 | 0.80 | CYP2A6 (1.00) | CYP2A6CA1CA2CHRNA7SMN1; SMN2 | |
| SCHEMBL2792315 | 0.78 | CYP2A6 (0.67) | CYP2A6CA1CA2CHRNA7SMN1; SMN2 | |
| SCHEMBL18666075 | 0.78 | CYP2A6 (0.67) | CYP2A6CA1CA2CHRNA7SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117729783-A | Tin-based perovskite photovoltaic device and preparation method thereof | 苏州大学 | 2024-03-19 | — | — | CN | claimed |
| EP-1633348-B1 | 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B sb 1 /sb RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARM INC (US) | 2008-10-08 | — | — | EP | claimed |
| EP-1794143-B1 | NOVEL BENZO-FUSED HETEROARYL SULFAMIDE DERIVATIVES USEFUL AS ANTICONVULSANT AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2008-07-09 | — | — | EP | claimed |
| US-20080125418-A1 | Benzimidazole derivatives and their use as kdr kinase protein inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-05-29 | — | — | US | claimed |
| EP-1877401-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | Elan Pharmaceuticals Inc. (US) | 2008-01-16 | — | — | EP | claimed |
| US-20070293476-A1 | CO-THERAPY FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS | SMITH-SWINTOSKY VIRGINIA L | 2007-12-20 | — | — | US | claimed |
| WO-2007095613-A2 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES AS NEUROPROTECTIVE AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-23 | — | — | WO | claimed |
| WO-2007095608-A2 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASE MODIFICATION OF EPILEPTOGENESIS | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2007-08-23 | — | — | WO | claimed |
| WO-2007095609-A2 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MANIA AND BIPOLAR DISORDER | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-23 | — | — | WO | claimed |
| US-20070191461-A1 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MIGRAINE | SMITH-SWINTOSKY VIRGINIA L | 2007-08-16 | — | — | US | claimed |
| WO-2006020681-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF UBIQUITIN CONJUGATING DISORDERS | HYGEIA BIOLOGICAL SYSTEMS (US) | 2006-02-23 | — | — | WO | claimed |
| US-20060035890-A1 | Compounds and methods for the treatment of ubiquitin conjugating disorders | AMIT BANERJEE | 2006-02-16 | — | — | US | claimed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | claimed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | claimed |
| US-20050020659-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. | 2005-01-27 | — | — | US | claimed |
| US-20050009894-A1 | Benzimidazole derivatives and their use as KDR kinase protein inhibitors | AVENTIS PHARMA S.A. (FR) | 2005-01-13 | — | — | US | claimed |
| WO-2004098589-A1 | 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | claimed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | claimed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | claimed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | CYP2A6 485/4885CA1 2872/4885CA2 740/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | CYP2A6 507/4885CA1 1766/4885CA2 649/4885 |
| US-20050020659-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | BDKRB1, BDKRB2, BRS3 | CYP2A6 1662/4885CA1 4468/4885CA2 4354/4885 |
| US-20070191461-A1 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MIGRAINE | SULT2A1, CNR2, FAAH2 | CYP2A6 658/4885CA1 2640/4885CA2 764/4885 |
| US-20080125418-A1 | Benzimidazole derivatives and their use as kdr kinase protein inhibitors | KDR, MUSK, FLT4 | CYP2A6 1442/4885CA1 4738/4885CA2 1870/4885 |
| US-20050009894-A1 | Benzimidazole derivatives and their use as KDR kinase protein inhibitors | KDR, MUSK, FLT4 | CYP2A6 1433/4885CA1 4733/4885CA2 1829/4885 |
| US-20070293476-A1 | CO-THERAPY FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS | GABBR1, SYNGR2, GABBR2 | CYP2A6 272/4885CA1 776/4885CA2 1100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.